Ysios Capital, a venture capital firm focused on life sciences, is launching InceptionBio, a €100 million fund dedicated to spinouts from institutions in Spain.
The move is a significant step in Spain’s ambition to become a leading global biotech hub, bolstered by government support and Ysios’s established track record.
InceptionBio will focus on early-stage biotech developers, including building and investing in spinouts through collaborations with universities, research centres, and scientific entrepreneurs.
The fund is backed by the Spanish Ministry of Science, Innovation and Universities’ Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through Innvierte. In January, Innvierte also backed the €30 million Montana Children’s Health fund to commercialise paediatric healthcare research.
InceptionBio already boasts a pipeline of potential investments and is targeting the creation of at least three spinouts this year.
Ysios Capital, which manages over €400 million in assets, has a history of success in the sector. Since 2008, it has fostered more than 100 collaborations with research institutions and backed more than 40 biotech companies, resulting in six IPOs on Nasdaq and the acquisition of ten other portfolio firms.
“We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them.
“InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain.”
Arturo Urrios, partner at Ysios Capital
The fund launch comes at a time when Spain is increasingly recognised for its advancements in areas such as gene therapy and personalised medicine. One such example is the first-time use of a gene therapy for the ultra-rare disease hereditary spastic paraplegia type 50 in a three-year-old patient at the SJD Barcelona Children’s Hospital last year.
